| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_77072f7e9fc93a45b026ee7fc3419830
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03942ca17769436e7ed365626838066f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-50 |
| filingDate |
2007-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a696b0d40fc3802b0afc0bb4c9bcc0b |
| publicationDate |
2008-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008079868-A1 |
| titleOfInvention |
Clonidine composition and method of use |
| abstract |
A pharmaceutical composition comprises clonidine or a pharmaceutically acceptable salt or prodrug thereof. The composition, when administered to a patient in an amount delivering a clonidine dose of about 0.1 to about 2 mg/day, exhibits clonidine release properties providing a 24-hour profile of plasma clonidine concentration that (a) does not substantially or protractedly fall below about 0.2 ng/ml and exhibits a peak concentration that is therapeutically effective and does not cause unacceptable side effects in the patient; and/or (b) exhibits a peak that substantially coincides with or closely anticipates a time of maximum plasma concentration of a catecholamine occurring in a diurnal cycle of a patient having a catecholamine-mediated disease or disorder. A method for treating a disease or disorder for which clonidine is indicated in a patient comprises administering such a composition one to three times daily in a dose of about 0.1 to about 2 mg/day to patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8999368-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9265733-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8968767-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9610243-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9211285-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9072727-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8231891-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9358223-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8557273-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9351959-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9833548-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9132085-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE48948-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8470360-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9132119-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8722079-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9585872-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9763917-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9770438-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8617583-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8946277-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9775800-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8629172-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10653619-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8822546-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8956641-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8889173-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9492461-B2 |
| priorityDate |
2006-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |